Adam Ingleton
Is intraprocedural intravenous aspirin safe for patients who require emergent extracranial stenting during mechanical thrombectomy?
Ingleton, Adam; Raseta, Marko; Chung, Rui-En; Kow, Kevin Jun Hui; Weddell, Jake; Nayak, Sanjeev; Jadun, Changez; Hashim, Zafar; Qayyum, Noman; Ferdinand, Phillip; Natarajan, Indira; Roffe, Christine
Authors
Marko Raseta
Rui-En Chung
Kevin Jun Hui Kow
Jake Weddell
Sanjeev Nayak
Changez Jadun
Zafar Hashim
Noman Qayyum
Phillip Ferdinand
Indira Natarajan
Christine Roffe c.roffe@keele.ac.uk
Abstract
Background: Intraoperative antiplatelet therapy is recommended for emergent stenting during mechanical thrombectomy (MT). Most patients undergoing MT are also given thrombolysis. Antiplatelet agents are contraindicated within 24 hours of thrombolysis. We evaluated outcomes and complications of patients stented with and without intravenous aspirin during MT.
Methods: All patients who underwent emergent extracranial stenting during MT at the Royal Stoke University Hospital, UK between 2010 and 2020, were included. Patients were thrombolysed before MT, unless contraindicated. Aspirin 500 mg intravenously was given intraoperatively at the discretion of the operator. Symptomatic intracranial haemorrhage (sICH) and the National Institutes for Health Stroke Scale score (NIHSS) were recorded at 7 days, and mortality and functional recovery (modified Rankin Scale: mRS ≤2) at 90 days.
Results: Out of 565 patients treated by MT 102 patients (median age 67 IQR 57–72 years, baseline median NIHSS 18 IQR 13–23, 76 (75%) thrombolysed) had a stent placed. Of these 49 (48%) were given aspirin and 53 (52%) were not. Patients treated with aspirin had greater NIHSS improvement (median 8 IQR 1–16 vs median 3 IQR −9–8 points, p=0.003), but there were no significant differences in sICH (2/49 (4%) vs 9/53 (17%)), mRS ≤2 (25/49 (51%) vs 19/53 (36%)) and mortality (10/49 (20%) vs 12/53 (23%)) with and without aspirin. NIHSS improvement (median 12 IQR 4–18 vs median 7 IQR −7–10, p=0.01) was greater, and mortality was lower (4/33 (12%) vs 6/15 (40%), p=0.05) when aspirin was combined with thrombolysis, than for aspirin alone, with no increase in bleeding.
Conclusion: Our findings based on registry data derived from routine clinical care suggest that intraprocedural intravenous aspirin in patients undergoing emergent stenting during MT does not increase sICH and is associated with good clinical outcomes, even when combined with intravenous thrombolysis.
Citation
Ingleton, A., Raseta, M., Chung, R., Kow, K. J. H., Weddell, J., Nayak, S., …Roffe, C. (2023). Is intraprocedural intravenous aspirin safe for patients who require emergent extracranial stenting during mechanical thrombectomy?. Stroke and Vascular Neurology, https://doi.org/10.1136/svn-2022-002267
Journal Article Type | Article |
---|---|
Acceptance Date | Sep 6, 2023 |
Online Publication Date | Oct 3, 2023 |
Publication Date | Oct 1, 2023 |
Deposit Date | Oct 9, 2023 |
Journal | Stroke & Vascular Neurology |
Electronic ISSN | 2059-8696 |
Publisher | BMJ Publishing Group |
Peer Reviewed | Peer Reviewed |
DOI | https://doi.org/10.1136/svn-2022-002267 |
Keywords | stents, thrombectomy, carotid stenosis, stroke, asprin |
You might also like
Downloadable Citations
About Keele Repository
Administrator e-mail: research.openaccess@keele.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search